Spotlight On... Chase Pharma raises $12M for Alzheimer's R&D; Trovagene axes CEO, CFO for snatching a business 'opportunity'; Keryx lifted by late-stage anemia data; and more...

Chase Pharmaceuticals, which is helmed by ex-Allergan ($AGN) president Doug Ingram, has raised $12 million, according to a filing with the SEC. The startup is working on a therapy that can be used to allow for higher doses of donepezil in treating Alzheimer's patients. The company has been keeping a low profile so far, and its website is largely a placeholder for what's being planned. Ingram was named CEO back in late 2015. Filing

@FierceBiotech: Sanofi hires research veteran to 'rejuvenate' its R&D division. Article | Follow @FierceBiotech

@JohnCFierce: This Merck/Harvard preclinical deal was my no.1  story last week. Which is cool. Report | Follow @JohnCFierce

> Shares of San Diego-based Trovagene ($TROV) took a dive after the company terminated CEO Antonius Schuh and CFO Stephen Zaniboni and filed a complaint on breach of fiduciary duty. Trovagene alleged that Schuh and Zaniboni "failed to present a lucrative corporate opportunity to Trovagene concerning promising new therapeutics in the field of precision medicine and instead took that opportunity for their own personal benefit." Release

> Keryx ($KERX) reported today that ferric citrate successfully treated iron deficiency among chronic kidney disease patients not yet on dialysis in a late-stage study. Shares spiked on the news. Story

Medical Device News

@FierceMedDev: Former Apple exec leading consumer-focused wellness blood testing startup Cor. Article | Follow @FierceMedDev

@EmilyWFierce: Veracyte brings in $45M to spur growth for molecular diagnostics business. Article | Follow @EmilyWFierce

> Rock West Medical scores $1.25M to advance ingestible endoscope. Article

> Affymetrix spurns bid by former execs in favor of $1.3B offer from Thermo Fisher. Report

Pharma News

@FiercePharma: Could J&J get an image boost from new health-oriented research? Experts say yes. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: Construction begins on Novo Nordisk's first US, API plant and first outside of Denmark. Report from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Looking for a respiratory edge, Boehringer teams with Propeller to test 'smart inhaler' for adherence. Article | Follow @CarlyHFierce

> In surprise decision, FDA blocks crucial cognitive claim for Takeda's Brintellix. Story

> Astellas cancer med Xtandi draws fire as U.S. lawmakers demand a pricing hearing. Article

Drug Delivery News

> On top of strong efficacy data, Alder migraine med shows potential for differentiated drug delivery. Item

> FDA encourages generic abuse-deterrent opioids in latest effort to tackle prescription drug abuse. Report

> Vygon opens Portuguese plant for manufacture of oncology devices that deliver chemotherapy. Story

> Capsugel eyeing IPO or sale for $5B+; Bayer, Danaher, Thermo Fisher and others interested. More

> Antibiotics get a boost from stabilizing frog foam delivery. Article

Pharma Manufacturing News

> FDA cites Lupin Indian plants for what drugmaker calls 'minor' issues. More

> PuraCap gets Puerto Rico plant with buyout of Blu Pharmaceuticals. Report

> Natco plant closed during floods written up by FDA. Story

> Novo starts construction on $1.8B plant in U.S. Article

> Boehringer Ingelheim snags second client for its China CMO operation. Item

Pharma Asia News

> Samsung Bioepis offers a glimpse at biosimilar manufacturing prowess. More

> Biocon wins key Japan approval for Lantus biosimilar. Story

> South Korean startup biotechs gain government, banking funding lift. Article

> Prosecutors heap more woe on OBI Pharma as 'insider trader' investigation deepens. Report

> India releases guidelines on biosimilar approval, manufacturing. Item

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.